Pharmacological Activation of Rev-erbα Attenuates Doxorubicin-Induced Cardiotoxicity by PGC-1α Signaling Pathway. (22nd February 2023)

• Record Type: Journal Article
• Authors: Zou, Runmei; Wang, Shuo; Cai, Hong; Wang, Yuwen; Wang, Cheng
• Other Names: Pandey Vivek Academic Editor.
• Is Part Of: Cardiovascular therapeutics. Volume 2023(2023)
• Publication Date: 2023-02-22
• Subjects: Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals; Cardiovascular Agents -- Periodicals; Cardiovascular Diseases -- drug therapy -- Periodicals; Agents cardiovasculaires -- Périodiques; Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques; 616.1005
• DOI: 10.1155/2023/2108584
• Languages: English
• ISSNs: 1755-5914

Abstract

Abstract : Background . Doxorubicin-induced cardiotoxicity has been closely concerned in clinical practice. Rev-erb α is a transcriptional repressor that emerges as a drug target for heart diseases recently. This study is aimed at investigating the role and mechanism of Rev-erb α in doxorubicin-induced cardiotoxicity. Methods . H9c2 cells were treated with 1.5 μ M doxorubicin, and C57BL/6 mice were treated with a 20 mg/kg cumulative dose of doxorubicin to construct doxorubicin-induced cardiotoxicity models in vitro and in vivo. Agonist SR9009 was used to activate Rev-erb α . PGC-1 α expression level was downregulated by specific siRNA in H9c2 cells. Cell apoptosis, cardiomyocyte morphology, mitochondrial function, oxidative stress, and signaling pathways were measured. Results . SR9009 alleviated doxorubicin-induced cell apoptosis, morphological disorder, mitochondrial dysfunction, and oxidative stress in H9c2 cells and C57BL/6 mice. Meanwhile, PGC-1 α and downstream signaling NRF1, TAFM, and UCP2 expression levels were preserved by SR9009 in doxorubicin-treated cardiomyocytes in vitro and in vivo. When downregulating PGC-1 α expression level by specific siRNA, the protective role of SR9009 in doxorubicin-treated cardiomyocytes was attenuated with increased cell apoptosis, mitochondrial dysfunction, and oxidative stress. Conclusion . Pharmacological activation of Rev-erb α by SR9009 could attenuate doxorubicin-induced cardiotoxicity through preservation of mitochondrial function and alleviation of apoptosis and oxidative stress. The mechanism is associated with the activation of PGC-1 α signaling pathways, suggesting that PGC-1 α signaling is a mechanism for the protective effect of Rev-erb α against doxorubicin-induced cardiotoxicity.